Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on October 31, 2019. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Protocol Participation Support

Awarded
75N91019R00016Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541990
New
Federal
Combined Synopsis/Solicitation for Commercial Items Agile Professional Services ("APS”) Department of the Army
Solicitation # W900KK-26-R-A023
The Agile Professional Services (APS) contract, solicitation W900KK-26-R-A023, is a 100% Total Small Business Set-Aside issued by the Army Contracting Command - Orlando. The primary objective is to transition the U.S. Army Capability Program Executive Simulation, Training, Test and Threat (CPE ST3) from a traditional staffing-based support model to a task-based, outcome-driven Agile delivery framework. This comprehensive commercial services vehicle consolidates previous professional support and SETA contracts to provide lifecycle support for over 370 products across 400 global locations. The scope includes a wide array of technical services such as artificial intelligence, cybersecurity, cloud computing, and financial management, with work performed at various government facilities, including primary sites in Orlando, Florida, and Redstone Arsenal, Alabama. The contract is structured as a Labor Hours/Time and Materials vehicle with a total performance period not to exceed 66 months, beginning February 15, 2027. This timeline consists of a six-month base period for agile development and transition, followed by four 12-month enterprise performance options, a six-month transition-out period, and a final six-month extension option. The total estimated contract value is 16.5 million dollars. Award will be based on the lowest Total Evaluated Price among offerors rated acceptable across technical factors, OCI mitigation, and a mandatory cybersecurity compliance gate requiring a NIST SP 800-171 Rev 2 score of 110 in SPRS. Key requirements include the proposal of an Agile Program Manager and the maintenance of a Top Secret facility security clearance.
W6QK Acc-Apg-Orlando

POSTED

about 21 hours ago

DEADLINE

in 5 days
NAICS: 541990
New
Federal
Water Resources Analytical and Professional Support Services - Multiple Award Task Order Contract (MATOC)
Solicitation # W912HQ27S0006
The US Army Corps of Engineers Mission Support Battalion is soliciting a Multiple Award Task Order Contract (MATOC) for Water Resources Analytical and Professional Support Services. This Indefinite Delivery Indefinite Quantity (IDIQ) contract is designed to provide the Institute for Water Resources (IWR) with technical research, analytical support, data management, facilitation, and training services that are not readily available within the agency. The contract has an anticipated maximum shared capacity of 49,500,000.00 dollars, with a period of performance consisting of one base year and four one-year option periods, plus a possible six-month extension. A partial small-business set-aside is anticipated based on specific tasks within the Performance Work Statement. The scope of work covers all Civil Works mission areas, including navigation, flood risk management, aquatic ecosystem restoration, hydropower, regulatory, recreation, and water supply. Key requirements include the development and maintenance of automated information systems, economic and socio-economic assessments, hydrologic and hydraulic engineering tools, and expertise in water security and integrated water resources management. The contract also involves support for dam and levee safety, conflict resolution, and financial analysis for public works infrastructure. Technical requirements include the provision of key personnel such as a Senior Project Integrator, IT Systems Engineer, and Cloud Systems Engineer, each with specific advanced degree and experience mandates. All deliverables must be provided with unlimited rights to the government, and the contractor is required to maintain a Task Delivery Order Quality Control Plan. Security requirements include a favorable National Agency Check for personnel accessing unclassified systems and adherence to DFARS 239.7602-2 regarding data storage within the United States. Submission requirements for the sources-sought phase include a completed questionnaire, a capabilities statement not exceeding 20 pages, and resumes for key personnel.
W4LD USA Hecsa

POSTED

about 21 hours ago

DEADLINE

in 17 days

AI Contract Overview

Show more

The National Cancer Institute's Lymphoid Malignancies Branch is seeking protocol participation support to advance the understanding and treatment of Adult T-cell Leukemia/Lymphoma, a rare and aggressive disease caused by the HTLV-1 retrovirus. The initiative involves several phase I and phase II clinical trials evaluating the safety and efficacy of various treatments, including Ruxolitinib, recombinant human IL-15 combined with Alemtuzumab or Mogamulizumab, and the collection of biological samples for immune response research. Because the majority of ATL cases are concentrated in the Caribbean basin, specifically Jamaica, the contract requires a partner with a strong local presence. The selected contractor will be responsible for identifying, diagnosing, and referring eligible patients to the established clinical protocols to ensure the success of these critical medical studies.

General Info

Agency

N/A

Contract Value

$99,398.27

NAICS

541990 - All Other Professional, Scientific, and Technical Services

Place of Performance

JAM

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

2 updates
PhaseAwarded
Posted

Presolicitation

Notice updated

Response deadline changed from Mar 27, 2019 to May 8, 2019. The notice description changed. The point of contact changed.

Notice updated

Response deadline changed from May 8, 2019 to May 9, 2019. The notice description changed.

Type Changed

Presolicitation → Solicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Margo KatzperContracting Officer

Full Description

Show more
Background An important mandate of the National Cancer Institute (NCI) is to develop new treatments for cancer. In a highly integrative approach, the Lymphoid Malignancies Branch (LYMB) of the NCI's Center for Cancer Research (CCR) utilizes recombinant molecules produced by NCI's Biopharmaceutical Development Program and commercial agents as potential immune system modulators. The LYMB Clinical Trials Team coordinates several phase I/phase II clinical trials under protocols that have been approved by the NCI's Institutional Review Board (IRB) for the study of adult T-cell leukemia/lymphoma (ATL). The LYMB's current portfolio consists of the following protocols: - NCT01712659: "Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering or Chronic Adult T-Cell Leukemia (ATL)." - NCT02689453: "Subcutaneous Recombinant Human IL-15 (rhIL-15) and Alemtuzumab for People with Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)." - NCT00001582: "Collection of Blood, Bone Marrow, and Tissue Samples for Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection." - LOI: "Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-cell Leukemia and Mycosis Fungoides/Sezary Syndrome." (Detailed information about each of the above listed trials is public information and can be accessed by visiting clinicaltrials.gov and searching by NCT number). Purpose. The overarching goal of LYMB's clinical trials is to improve the understanding and treatment of ATL. ATL is a rare and highly aggressive lymphoproliferative disease that results from chronic infection with the retrovirus Human T-cell Lymphotropic Virus type 1 (HTLV-1). HTLV-1 is most pervasive in the Caribbean basin-specifically Jamaica-where the majority of ATL cases reside. Access to this population is crucial to the success of LYMB's study; therefore, LYMB requires a contractor with a strong presence in Jamaica that is capable of effectively identifying, diagnosing and referring ATL patients to LYMB's protocols.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS